Advertisement

Advancing Parkinson’s Disease and Treatment of Motor Complications

  • Ryan J. Uitti
Part of the Current Clinical Practice book series (CCP)

Abstract

This chapter addresses issues related to the diagnosis and treatment of motor dysfunction in advancing Parkinson’s disease (PD). The format, designed for use by the clinician, identifies keys to a pertinent history and physical examination and suggests treatment strategies for specific clinical situations. A discussion of other practical issues follows this section.

Keywords

Dopamine Agonist Motor Fluctuation Levodopa Dose COMT Inhibitor Antiparkinsonian Medication 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Selected Reading

  1. Ahlskog JE. Medical treatment of later-stage motor problems of Parkinson disease. Mayo Clin Proc 1999; 74: 1239–1254.PubMedCrossRefGoogle Scholar
  2. Ahlskog JE, Muenter MD, McManis PG, Bell GN, Bailey PA. Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson’s disease. Mayo Clin Proc 1988; 63: 876–886.PubMedCrossRefGoogle Scholar
  3. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997; 49: 162–168.PubMedCrossRefGoogle Scholar
  4. Olanow CW, Koller WC. An algorithm (decision tree) for the management of Parkinson’s disease: treatment guidelines. American Academy of Neurology. Neurology 1998; 50 (Suppl 3): S1–57.PubMedCrossRefGoogle Scholar
  5. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson’s disease patients. Ann Neurol 1997; 42: 747–755.CrossRefGoogle Scholar
  6. Rajput AH, Martin W, Saint-Hilaire MH, Dorflinger E, Pedder S. Tolcapone improves motor function in parkinsonian patients with the “wearing-off” phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 1997; 49: 1066–1071.PubMedCrossRefGoogle Scholar
  7. Rascol O, Lees AJ, Senard JM, Pirtosek Z, Montastruc JL, Fuell D. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson’s disease. Clin Neuropharmacol 1996; 19: 234–245.PubMedCrossRefGoogle Scholar
  8. Uitti RJ, Ahlskog JE. Comparative review of dopamine receptor agonists in Parkinson’s disease. CNS Drugs 1996; 5: 369–388.CrossRefGoogle Scholar
  9. Uitti RJ, Ahlskog JE, Maraganore DM, Muenter MD, Atkinson EJ, Cha RH, O’Brien PC. Levodopa therapy and survival in idiopathic Parkinson’s disease: Olmsted County project. Neurology 1993; 43: 1918–1926.PubMedCrossRefGoogle Scholar
  10. Uitti RJ, Rajput AH, Ahlskog JE, Offord KP, Schroeder DR, Ho MM, Prasad M, Rajput A, Basran P. Amantadine treatment is an independent predictor of improved survival in Parkinson’s disease. Neurology 1996; 46: 1551–1556.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2000

Authors and Affiliations

  • Ryan J. Uitti

There are no affiliations available

Personalised recommendations